Day One Biopharmaceuticals/$DAWN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Ticker
$DAWN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
ISIN
US23954D1090
Website
DAWN Metrics
BasicAdvanced
$657M
-
-$0.71
-1.30
-
Price and volume
Market cap
$657M
Beta
-1.3
52-week high
$16.75
52-week low
$6.08
Average daily volume
1.3M
Financial strength
Current ratio
10.624
Quick ratio
10.257
Long term debt to equity
0.595
Total debt to equity
0.608
Profitability
EBITDA (TTM)
-189.212
Gross margin (TTM)
94.96%
Net profit margin (TTM)
-42.66%
Operating margin (TTM)
-115.22%
Effective tax rate (TTM)
-11.53%
Revenue per employee (TTM)
$890,000
Management effectiveness
Return on assets (TTM)
-27.81%
Return on equity (TTM)
-17.80%
Valuation
Price to revenue (TTM)
3.892
Price to book
1.37
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
-3.808
Free cash flow yield (TTM)
-26.26%
Free cash flow per share (TTM)
-170.16%
Growth
Earnings per share change (TTM)
-71.65%
3-year earnings per share growth (CAGR)
-42.09%
What the Analysts think about DAWN
Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.
Bulls say / Bears say
Day One Biopharmaceuticals reported Q1 2025 net product revenue of $30.5 million for OJEMDA™ (tovorafenib), marking a 16% increase in prescriptions compared to Q4 2024. (dayonebio.com)
Analysts have set an average 12-month price target of $34.13 for DAWN, indicating a potential upside of over 320% from the current price. (tipranks.com)
The company maintains a strong financial position with $473 million in cash, cash equivalents, and short-term investments as of Q1 2025, providing ample resources for ongoing research and development. (dayonebio.com)
Despite revenue growth, Day One Biopharmaceuticals reported a net loss of $0.35 per share in Q1 2025, highlighting ongoing profitability challenges. (nasdaq.com)
The company's stock has declined approximately 41% since the beginning of the year, underperforming the S&P 500's decline of 3.9%. (nasdaq.com)
Analyst consensus estimates for earnings per share have fallen by 12% as of April 21, 2025, reflecting concerns about the company's future profitability. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
DAWN Financial Performance
Revenues and expenses
DAWN Earnings Performance
Company profitability
DAWN News
AllArticlesVideos
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
GlobeNewsWire·2 weeks ago
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
GlobeNewsWire·2 months ago
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Day One Biopharmaceuticals stock?
Day One Biopharmaceuticals (DAWN) has a market cap of $657M as of June 27, 2025.
What is the P/E ratio for Day One Biopharmaceuticals stock?
The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of June 27, 2025.
Does Day One Biopharmaceuticals stock pay dividends?
No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Day One Biopharmaceuticals dividend payment date?
Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.
What is the beta indicator for Day One Biopharmaceuticals?
Day One Biopharmaceuticals (DAWN) has a beta rating of -1.3. This means that it has an inverse relation to market volatility.